173 related articles for article (PubMed ID: 38552216)
1. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
[TBL] [Abstract][Full Text] [Related]
2. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
5. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
7. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
8. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
9. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
10. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
Liu Z; Cheng X; Pang B; Wang S; Liu B; Cao C; Qian R; Liang W; Zhu Y; Li P; Gao Y
Int Immunopharmacol; 2022 Mar; 104():108399. PubMed ID: 35008004
[TBL] [Abstract][Full Text] [Related]
11. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():668391. PubMed ID: 34539622
[TBL] [Abstract][Full Text] [Related]
12. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
13. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
14. Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of
Liu Z; Yang L; Xie Z; Yu H; Gu T; Shi D; Cai N; Zhuo S
Oncol Res; 2024; 32(5):965-981. PubMed ID: 38686055
[TBL] [Abstract][Full Text] [Related]
15. CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.
Jia Y; Cheng X; Liang W; Lin S; Li P; Yan Z; Zhang M; Ma W; Hu C; Wang B; Liu Z
Curr Res Transl Med; 2022 Sep; 70(4):103345. PubMed ID: 35487167
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas.
Wang ZL; Zhang CB; Cai JQ; Li QB; Wang Z; Jiang T
J Exp Clin Cancer Res; 2015 Oct; 34():127. PubMed ID: 26502731
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma.
Wang J; Liu Y; Qian M; Xu W; Chen J; Deng Y; Luo R; Chen J; Jia W; Liu L; Tian C
Biochem Biophys Res Commun; 2024 Jun; 711():149894. PubMed ID: 38603834
[TBL] [Abstract][Full Text] [Related]
18. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
19. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
